904 institutions hold shares in AstraZeneca PLC (AZN), with 131.27k shares held by insiders accounting for 0.00% while institutional investors hold 15.68% of the company’s shares. The shares outstanding are 2.62B, and float is at 2.60B with Short Float at 3.65%. Institutions hold 15.67% of the Float.
The top institutional shareholder in the company is Primecap Management Company with over 50.11 million shares valued at $2.5 billion. The investor’s holdings represent 1.91% of the AZN Shares outstanding. As of Dec 30, 2020, the second largest holder is Wellington Management Group, LLP with 48.59 million shares valued at $2.43 billion to account for 1.85% of the shares outstanding. The other top investors are Capital International Investors which holds 25.99 million shares representing 0.99% and valued at over $1.3 billion, while FMR, LLC holds 0.97% of the shares totaling 25.4 million with a market value of $1.27 billion.
AstraZeneca PLC (NASDAQ: AZN) is -0.92% lower on its value in year-to-date trading and has touched a low of $42.80 and a high of $64.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AZN stock was last observed hovering at around $49.72 in the last trading session, with the day’s loss setting it -0.19% off its average median price target of $65.41 for the next 12 months. It is also 40.41% off the consensus price target high of $83.12 offered by 25 analysts, but current levels are -4.19% lower than the price target low of $47.54 for the same period.
Currently trading at $49.53, the stock is 0.33% and -1.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.96 million and changing -0.38% at the moment leaves the stock -6.54% off its SMA200. AZN registered 13.13% gain for a year compared to 6-month loss of -9.62%. The firm has a 50-day simple moving average (SMA 50) of $49.44 and a 200-day simple moving average (SMA200) of $51.90.
The stock witnessed a 5.03% gain in the last 1 month and extending the period to 3 months gives it a -1.30%, and is -0.34% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.26% over the week and 1.63% over the month.
AstraZeneca PLC (AZN) has around 76100 employees, a market worth around $130.70B and $26.62B in sales. Current P/E ratio is 40.70 and Fwd P/E is 15.12. Profit margin for the company is 12.00%. Distance from 52-week low is 15.72% and -23.73% from its 52-week high. The company has generated returns on investments over the last 12 months (12.20%).
AstraZeneca PLC (AZN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for AstraZeneca PLC (AZN) is a “Buy”. 25 analysts offering their recommendations for the stock have an average rating of 1.20, where 1 rate it as a Hold and 2 think it is a “Overweight”. 21 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
AstraZeneca PLC is expected to release its quarterly report on 07/29/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $7.22B over the same period.The EPS is expected to grow by 137.20% this year, but quarterly earnings will post 19.80% year-over-year. Quarterly sales are estimated to grow 13.70% in year-over-year returns.
AstraZeneca PLC (AZN): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 35.79% up over the past 12 months and Biogen Inc. (BIIB) that is -11.91% lower over the same period. Johnson & Johnson (JNJ) is 26.41% up on the 1-year trading charts. Short interest in the company’s stock has risen 17.95% from the last report on Feb 11, 2021 to stand at a total of 77.9 million short shares sold with a short interest ratio of 8.15.